Puberty blockers in the UK: the evidence, the ban and the trial

Why did the UK stop routine prescription of puberty blockers, and what is the proposed clinical trial?

Puberty blockers are gonadotrophin-releasing hormone analogues, or GnRHa medicines. They suppress the hormonal signals that drive puberty. In paediatric medicine they have established licensed uses, including treatment for central precocious puberty. Their use for children and adolescents experiencing gender incongruence or gender dysphoria is different: it is off-label, meaning that the medicines have not been authorised by the regulator for that indication.

Background

Puberty blockers are gonadotrophin-releasing hormone analogues, or GnRHa medicines. They suppress the hormonal signals that drive puberty. In paediatric medicine they have established licensed uses, including treatment for central precocious puberty. Their use for children and adolescents experiencing gender incongruence or gender dysphoria is different: it is off-label, meaning that the medicines have not been authorised by the regulator for that indication.

For many years, the Tavistock and Portman NHS Foundation Trust’s Gender Identity Development Service, usually known as GIDS, was England’s national specialist service for children and young people. It prescribed puberty blockers to a selected group of patients, initially within a research protocol and later in ordinary clinical practice. The service was placed under intense scrutiny because of rising referrals, long waits, clinical disagreements and concern that a highly specialised national service could not provide sufficiently broad assessment of young people’s mental health, neurodevelopmental needs, family circumstances and safeguarding issues.

NHS England commissioned Dr Hilary Cass, a former president of the Royal College of Paediatrics and Child Health, to review the service. The resulting Cass Review examined the service model and commissioned systematic evidence reviews from the University of York. In parallel, NHS England moved away from the Tavistock model: GIDS was brought to a managed closure, and new regional Children and Young People’s Gender Services began operating in London and the North West in April 2024 (NHS England, 2024).

The legal history is often misreported. In Bell v Tavistock, the High Court ruled in December 2020 that it was highly unlikely that a child aged 13 or under could consent to puberty blockers and that clinicians might need court approval in some cases involving 14- and 15-year-olds. In September 2021, however, the Court of Appeal overturned that declaration. It held that questions of Gillick competence and consent should be decided clinically and on the facts of individual cases, rather than through a general judicial declaration (Bell v Tavistock, Court of Appeal, 2021). There was no Supreme Court judgment in Bell; the Court of Appeal decision remains the final appellate ruling in that case.

What the documents say

NHS England and the Cass Review

NHS England’s clinical policy of 12 March 2024 states that puberty-suppressing hormones are not available as a routine commissioning treatment for under-18s with gender incongruence or dysphoria. It records that the 2020 NICE evidence review found nine observational studies and assessed the certainty of evidence for outcomes including mental health, body image, psychosocial functioning and gender dysphoria as very low. NHS England also found limited short- and long-term safety data, including concern that treatment may reduce the expected increase in bone density during puberty (NHS England, 2024).

The Cass Review did not state that every young person prescribed a blocker had been harmed, nor did it find that no young person could benefit. Its central finding was evidential: clinicians and families could not reliably weigh benefits against harms because the research base was inadequate. It described the rationale for early puberty suppression as unclear, reported weak evidence of an effect on dysphoria-related distress and mental or psychosocial health, and identified uncertainty around cognitive and psychosexual development. It also noted that bone density is compromised during suppression (Cass Review, 2024).

Cass therefore recommended that puberty blockers should only be available under the oversight of a national multidisciplinary team or as part of a formal clinical trial, within a wider programme that also investigates psychosocial interventions and later hormone treatment. The recommendation was not simply to stop treatment: it was to replace a narrow, medicine-led pathway with comprehensive assessment and support.

The restrictions and the meaning of “ban”

“Ban” is useful shorthand, but it can obscure important distinctions. The NHS decision was a commissioning decision: routine NHS prescription ceased in England in March 2024. Separate regulations restricted initiation through NHS primary care. The medicines themselves remain available for other medical conditions, including precocious puberty.

The statutory restrictions addressed another route: private and overseas prescriptions. An emergency order came into force in Great Britain on 3 June 2024, restricting the sale and supply of specified GnRHa medicines to new under-18 patients for gender incongruence or dysphoria. Existing patients were subject to transitional arrangements. The Department of Health and Social Care, working with Northern Ireland, subsequently introduced an indefinite order in December 2024. The Order restricts new private UK prescriptions and prescriptions from European Economic Area or Swiss prescribers for under-18s in this context, while allowing exceptions including lawful research and certain existing treatment arrangements (DHSC, 2024).

The Commission on Human Medicines supported indefinite restrictions while safeguards were developed. Its advice focused not only on uncertainty about clinical outcomes, but on the prescribing environment: fragmented care, insufficient specialist oversight and prescriptions being obtained through remote or overseas routes. The Order is scheduled for review in 2027 (CHM, 2024).

What PATHWAYS proposes

PATHWAYS is a research programme commissioned and funded by NHS England and the National Institute for Health and Care Research, co-sponsored by King’s College London and South London and Maudsley NHS Foundation Trust. Its main clinical trial concerns young people attending NHS gender services who have a diagnosis of gender incongruence, persistent distress and have not previously taken puberty blockers or cross-sex hormones.

The trial design offers eligible participants puberty suppression either immediately or after a one-year delay. The groups are to be compared over two years for quality of life, mental health, physical development, cognitive function and gender-related distress. Participants undergo regular clinical reviews, blood tests and scans. A linked observational study, PATHWAYS HORIZON, follows young people who are not receiving GnRHa, while PATHWAYS CONNECT includes more intensive cognitive and brain-imaging work for a subgroup (NIHR, 2026).

Regulatory approval was initially granted in November 2025. In February 2026, the Medicines and Healthcare products Regulatory Agency raised concerns and paused the preliminary work. A revised protocol was approved in June 2026 with strengthened safeguards, including minimum ages, more explicit stopping criteria concerning bone health, cognition and vaginal bleeding, and clearer fertility-preservation information. On 31 July 2026, Mr Justice Chamberlain refused permission for judicial review in Bayswater Support Group, Bell and Esses v Health Research Authority and Secretary of State for Health and Social Care. The court did not declare puberty blockers safe or effective; it found no arguable legal basis to overturn the regulators’ approval of the trial (HRA, 2026; Bayswater Support Group, 2026).

The positions

Supporters of the restrictions argue that the NHS was right to stop treating a major developmental intervention as routine where evidence of benefit is very uncertain and important harms remain unresolved. They emphasise that puberty is not an inconvenience to be paused without consequence, and that distressed children deserve careful assessment rather than a default pathway towards medicalisation. This position draws directly on the Cass Review, NHS England’s policy and CHM safety advice.

Critics argue that stopping routine access has caused distress to young people who experience puberty as acutely painful, and that observational evidence and clinical experience should not be dismissed because randomised trials are difficult in this field. They also raise ethical concerns about a trial in which access to treatment may depend on enrolment, and about the impact of delaying treatment for participants allocated to the delayed-start group. Trans advocacy organisations have welcomed the court’s July 2026 decision because it permits the study to proceed, while continuing to argue for timely, respectful healthcare (TransActual, 2026).

The common ground is more substantial than public debate suggests. All sides agree that children require compassionate support, that serious mental-health needs must be addressed, and that the evidence base should be stronger. The dispute is over what ethical caution requires when evidence is weak: a presumption against routine medical intervention, or continued individualised access while better evidence is gathered.

Interpretation

Beyond Gender’s reading is that the UK stopped routine prescription because the previous system had normalised an experimental use of powerful endocrine medicines without the quality of evidence normally expected for a paediatric treatment with potentially lifelong implications. The decisive issue was not whether some young people report relief, but whether the NHS could demonstrate that expected benefits outweighed known and unknown risks for the patients being treated. It could not.

The Cass Review matters because it reframed the question from affirmation of an asserted identity to ordinary paediatric medicine: diagnosis, differential assessment, co-occurring conditions, safeguarding, developmental time and informed consent. That is a necessary correction. A child’s distress is real; it does not follow that suppressing normal puberty is the right response.

PATHWAYS is an attempt to answer questions that should have been resolved before routine prescribing expanded. Its safeguards and delayed-start design acknowledge uncertainty, but they do not remove the ethical difficulty. The trial’s eventual value will depend on transparent publication, adequate follow-up, clinically meaningful outcomes, full reporting of adverse events and honest attention to participants who discontinue treatment or later change course.

Open questions

Can PATHWAYS distinguish a treatment effect from the benefit of intensive specialist attention, repeated monitoring and family support? Will its participant group be representative of the much wider population referred to NHS gender services, including young people with complex mental-health, autism-spectrum, eating-disorder or safeguarding presentations? And will the follow-up be long enough to assess bone health, fertility, sexual development, cognitive outcomes and later use of cross-sex hormones?

There are also questions for Parliament and government. The 2024 Order is to be reviewed in 2027, but what evidence threshold will be required before restrictions are lifted, maintained or amended? How will the Department of Health and Social Care ensure consistent rules across the UK? And how will the Department for Education’s developing guidance on gender-questioning children in schools align with the clinical reality that identity-related distress requires safeguarding, parental involvement and time for exploration rather than institutional certainty?

On the UK timeline

Episodes on this subject

REPATH LAUNCH

REPATH LAUNCH

Where Did Psychotherapy Go Wrong? | Ian Cox